- Open Access
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice
© Westwood et al; licensee BioMed Central Ltd. 2010
- Received: 12 January 2010
- Accepted: 28 April 2010
- Published: 28 April 2010
Combination immunotherapies can be effective against subcutaneous tumors in mice but the effect against orthotopic malignant disease is less well characterized. In particular, a combination of three agonist antibodies, termed Tri-mAb, consisting of anti-DR5, anti-CD40 and anti-CD137 has previously been demonstrated to eradicate a large proportion of subcutaneous renal cell carcinoma (Renca) tumors (75% long-term survival), but the effect against orthotopic disease is not known.
To determine the relative response of orthotopic tumors, we inoculated Renca into the kidney followed by treatment with Tri-mAb.
We found that orthotopic tumors responded much less to treatment (~13% survival), but a significant improvement in survival was achieved through the addition of IL-2 to the treatment regimen (55% survival). All three agonist antibodies and high dose IL-2, 100,000 IU for up to six doses, were required. CD8+ T cells were also required for optimal anti-tumor responses. Coadministration of IL-2 led to enhanced T cell activity as demonstrated by an increased frequency of IFN-gamma-producing T cells in tumor-draining lymph nodes, which may have contributed to the observed improvement of therapy against kidney tumors.
Responses of subcutaneous tumors to immunotherapy do not necessarily reflect how orthotopic tumors respond. The use of combination immunotherapy stimulating multiple facets of immunity and including cytokine support for T cells can induce effective anti-tumor responses against orthotopic and metastatic tumors.
- Subcutaneous Tumor
- Kidney Tumor
- Orthotopic Tumor
- Agonist Antibody
- Immunogenic Cell Death
Immunotherapies involving combinations of various immunomodulating agents are demonstrating considerable promise for the treatment of cancer. In particular, the use of agents that together stimulate multiple immune components can mediate regression of established tumors. Important steps to achieve robust anti-tumor immunity include tumor antigen release, optimal antigen presentation to specific T cells and costimulation of T cells resulting in optimal activation and expansion of tumor-specific T cells.
Monoclonal antibodies (mAb) targeting death receptors expressed on a range of transformed cells  can mediate apoptosis of a proportion of tumor cells leading to induction of tumor-specific T cells and inhibition of tumor growth in preclinical mouse models. An agonistic antibody targeting CD40 expressed on antigen presenting cells has been demonstrated to lead to activation of APCs and the generation of CTL and eradication of lymphoma in mice. Triggering the costimulatory molecule CD137 (4-1BB) expressed on activated T cells  has been demonstrated to lead to increases in T cell numbers and activation [5, 6]. Agonistic antibodies specific for CD137 can inhibit tumor growth in mice .
However, this use of single immunomodulators against established disease has been of limited effect in both preclinical and early phase clinical trials [8–10]. The use of immunomodulating agents in combination with chemotherapy is demonstrating promise, and drug-induced tumor apoptosis and immune-potentiation are thought to play a role in therapy using combined agents [11, 12].
Combinations of immune agonistic antibodies have also demonstrated effectiveness against tumors of various histologies when implanted subcutaneously. A combination of three antibodies targeting DR5, CD40 and CD137, termed Tri-mAb, was able to induce complete regression of syngeneic breast and kidney cancers located subcutaneously . In another study using this combination approach, NKT cell glycolipid ligands were demonstrated to be able to substitute for CD40 ligation and induce tumor regression . A subsequent study demonstrated that the inclusion of IL-21 in the treatment schedule could enhance the efficacy of Tri-mAb therapy against subcutaneous disease and small metastases .
Since tumor growth and responses can vary depending on size and anatomical location, and established orthotopic metastatic cancer is considered more difficult to treat than subcutaneous disease, in the current study we sought to determine the effect of Tri-mAb against established orthotopic and metastatic renal cell carcinoma without nephrectomy and ascertain if treatment could be optimized using cytokine support.
Cell lines and mice
Renca is a kidney cancer cell line of BALB/c mice . This tumor cell line was maintained at 37°C and 5% CO2 in RPMI medium, supplemented with 10% heat-inactivated fetal calf serum (FCS) (Moregate Biotech, Bulimba, QLD, Australia), 2 mM glutamine (JRH Biosciences, Brooklyn, VIC, Australia), 100 U/ml penicillin, and 100 μg/ml streptomycin (both from Sigma, Castle Hill, NSW, Australia).
BALB/c mice were purchased from The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, and from Animal Resource Centre, Perth, Western Australia. They were housed in specific pathogen free conditions. Mice of 6 to 20 weeks of age were used in experiments, and experiments were performed according to The Peter MacCallum Cancer Centre Animal Experimentation Ethics Committee guidelines.
Tumor growth in mice
BALB/c mice were inoculated subcapsule into the kidney with 1 × 105 Renca cells. Treatment started 10 - 11 days later, after randomization of mice into groups. Tri-mAb consisted of a mixture of MD5.1 (anti-death receptor-5, DR5), FGK-45 (anti-CD40) and 3H3 (anti-4-1BB) in equal proportions. Each antibody was determined to be endotoxin free by LAL test. Different batches of the individual mAbs of Tri-mAb were titrated in this study so that 50-80% tumor regression of s.c. tumors was achieved, as some batches of antibodies were toxic at the highest dose of 100 μg each mAb per dose. Each dose of Tri-mAb was injected intra-peritoneally every 3 - 4 days for a total of 3 doses. Other groups additionally received 100,000 IU recombinant human IL-2 (NCI Preclinical Repository, Frederick, MD, USA) in 200 μl PBS i.p. every day for up to 6 doses or until mice could not tolerate any more. Some groups received PBS or control MAC4 rat IgG2a and UC8-1B9 hamster IgG instead of Tri-mAb, at 100 μg each mAb/200 μl/dose intra-peritoneally every 3 - 4 days for a total of 3 doses. Tumor progression was determined by survival of mice, which was defined as time until mice became moribund, at which point they were euthanized. Subcutaneous tumors were established by injection of 2 × 105 Renca cells in 100 μl PBS into the abdominal area of mice after fur in that area was trimmed. In some experiments CD8+ T cells were depleted using the mAb, clone 53.6.72, administered 200 μg 1 day prior to tumor injection and 100 μg on the day of tumor injection followed by twice weekly injections of 100 μg for 24 days.
Intracellular IFN-γ assay
Mice were injected with 2 × 105 Renca s.c. into the upper foot. Some groups received Tri-mAb on days 10 and 13, and/or IL-2 at the dose of 100,000 IU/200 μl i.p. on days 10, 11 and 13. Control mice received MAC4 plus UC8-1B9 i.p. On day 14, mice from each group were culled and popliteal lymph node cells were harvested, teased between forceps, filtered through a 70 μm filter, and individually stimulated on anti-CD3 coated plates (0.13 μg per well). 1 × 106 cells were placed in 0.5 ml media in a 48-well plate. The plates were incubated for 18 hours at 37°C in 5% CO2, and GolgiStop (BD Biosciences, San Jose, CA) was added for the last 12 hours. Cells were harvested the next day and stained and assessed by flow cytometry for intracellular IFNγ using a Cytofix/Cytoperm Plus Fixation/Permeabilization kit (BC Biosciences Cat # 554715), following the manufacturer's directions. Antibodies used in this study were CD8α-FITC clone 53-6.7 (BD), TCRβ-APC clone H57.597 (BD), and IFNγ-PE clone XMG1.2 (BD). Cells were analyzed by flow cytometry using a FACS Calibur (BD).
Statistical analysis was performed with StatsDirect software using Log rank analysis for comparing mouse survival data, and a Mann-Whitney Test for comparing cytokine secretion from different treatment groups. Data producing a P value of < 0.05 was considered to be significant.
Tri-mAb therapy is less effective against tumors inoculated into the kidney
Previous studies have demonstrated that administration of Tri-mAb (anti-DR5 + anti-CD40 + anti-CD137) to mice bearing subcutaneous Renca tumors regularly resulted in complete regression of 50-80% (mean 70.8% ± 6.4) of tumors . In order to determine if this degree of effectiveness could be achieved against orthotopic metastatic disease, we inoculated Renca directly into the kidney and determined the effect of Tri-mAb on mouse survival compared to mice bearing subcutaneous tumors. Treatment with Tri-mAb began 10 days after inoculation of Renca tumor cells, by which time s.c. tumors were approximately 30 mm2 in size, and primary kidney tumors were approximately 10 mm2. Micrometastases were also present at day 10 in the lungs of mice bearing kidney tumors.
The effectiveness of Tri-mAb against orthotopic kidney cancer is enhanced by coadministration of high-dose IL-2
In the experiments described above, we used high dose IL-2 at 100,000 IU administered intraperitoneally daily for 5 days. To determine if a similar enhancement of therapy could be achieved with lower doses of IL-2, we treated tumor-bearing mice with Tri-mAb in combination with low dose (10,000 IU) or medium dose (50,000 IU) or high dose (100,000 IU) IL-2 daily for 5 days and monitored survival.
All three antibodies are necessary for optimal anti-tumor effects and treatment induces anti-tumor immunological memory
Previous studies have shown that subcutaneous tumor-bearing mice surviving long-term after Tri-mAb therapy are resistant to tumor rechallenge, demonstrating immunological memory formation against tumor-associated antigens . To determine if memory was similarly invoked in mice bearing orthotopic kidney cancer following the inclusion of IL-2 in the treatment regimen, we rechallenged surviving mice with Renca (2 × 105, subcutaneously).
IL-2 increases the frequency of IFN-γ-producing T cells, and CD8+ T cells are necessary for optimal anti-tumor activity
Experimental therapies developed on the basis of responses of ectopic inoculation of tumor cells subcutaneously can be performed quickly and can teach us much about the potential of various therapeutics and give us mechanistic insight into therapeutic effects. Orthotopic metastatic cancer models are more complex and are considered more difficult to treat than subcutaneous tumors. One of the most promising therapies we have recently encountered consists of three agonist antibodies (Tri-mAb) administered systemically to mice bearing subcutaneous DR5+ tumors. However, we did not know if the remarkable tumor eradication rates of approximately 70% could be achieved against orthotopic disease. In experiments described herein, we found that orthotopic kidney cancer was indeed much more difficult to treat than subcutaneous disease, but response rates of mice bearing orthotopic disease could be significantly raised (to ~55%) by the addition of high dose IL-2 to the treatment regimen.
The reasons for poorer responses of orthotopic disease to immunotherapy are not clear, but it is unlikely to simply be an issue of tumor burden, since subcutaneous tumors are larger than the combined mass of primary kidney tumors and micrometastases on day 10 after inoculation, and yet subcutaneous tumors respond better. Possible reasons include differences in tumor microenvironment in which orthotopic disease and metastases have a more immunosuppressive environment perhaps mediated by regulatory cells and/or immunosuppressive cytokines. Another potential reason may lie in inherent differences in lymph nodes draining subcutaneous sites and those draining internal sites. In any event, coadministration of IL-2 was demonstrated to increase the proportion of T cells able to produce IFN-γ upon stimulation, which likely contributed to the enhanced therapeutic effect against orthotopic disease. This may have reflected increases in the frequency or activity of tumor associated antigen-specific T cells, but the specific TAA are not known for Renca, and without this knowledge it is technically difficult to demonstrate tumor-specific activity from freshly isolated lymphoid cells. In any event, it is unlikely that fetal-calf serum antigens played a role in the differential responses since cells injected into both sites were cultured the same, and it is likely fetal calf antigens were not present at the time of treatment since tumors were established for 10 days before treatment.
Tri-mAb therapy is dependent on the expression of DR5 on tumor cells, and ligation of DR5 is thought to induce immunogenic cell death in a proportion of tumor cells, thereby liberating TAA for recognition by the immune system. Nevertheless, it is possible to extend this type of therapy to DR5-refractory tumors by using some chemotherapeutic agents that can also induce immunogenic cell death resulting in enhanced immune responses against tumors when combined with anti-CD40 and anti-CD137 [17, 18]. Other orthotopic models of cancer do exist including MC38 mouse colon carcinoma and, although not established in our laboratory, it would be of interest to determine if the current observations extend to these models.
Other combination immunotherapies have demonstrated potential for the eradication of large proportions of established subcutaneous tumors in mice including the use of Toll-like receptor agonists in combination with anti-CD137 . It would be of interest to determine if coadministration of cytokine can enhance therapy against more established subcutaneous disease or orthotopic disease in those settings.
Other forms of therapy have been demonstrated to impact on orthotopic kidney cancer in mice, including the use of IL-2 in combination with anti-CD40  or IL-12  in the Renca system. However, part of the novelty of our observations in the current study lie in the advanced nature of orthotopic disease and the ability to produce a large proportion of long-term survivors that have no evidence of disease upon conclusion of experiments without the need for surgical resection of the primary.
Coadministration of IL-2 has long been known to enhance immunotherapies such as adoptive transfer of tumor-specific T cells . In addition, alternate cytokines can be used with benefit in combination immunotherapies, including IL-15  and IL-21 . Since IL-2 can be associated with toxicity, it would be of interest to determine if these cytokines can be of benefit against orthotopic disease in the current model.
The reasons for the enhancement of therapy for IL-2 are not fully known, although there could be a contribution from increased effector function of T cells mediated by IL-2 . However, IL-2 has also been demonstrated to play a role in the expansion of regulatory T cells , and it would be of interest in future studies to determine the effect of IL-2 on regulatory T cell numbers and function in this tumor model. Similarly, we have no insight into the relative contribution of CD4+ helper T cells in this therapy or indeed if they are required at all once IL-2 has been exogenously provided, but it would be of interest to derive such insight in future studies.
There are considerable challenges in the development of optimal immunotherapies for cancer, and it is generally of limited use to stimulate a single immune component, rather it will likely be necessary to use several immune modulators in concert that stimulate diverse immune components such as antigen presentation and T cells, together with activation of innate immune components to produce site-specific inflammatory signals. The choice of appropriate tumor models also represent a challenge, and while subcutaneous models can provide rapid advances and direct further investigations, orthotopic tumor models such as that described herein may provide more physiologic settings in which to determine treatment effectiveness and identify mechanisms. Indeed, the data presented here suggests that the therapeutic efficacy observed in subcutaneous models following immunotherapy may not extend to tumors in other locations. The investigation of rationally designed combination immunotherapies in orthotopic models of malignancy may lead to effective therapeutic options for cancer patients.
This work was supported by grants from The National Health and Medical Research Council of Australia (NHMRC), The Cancer Council of Australia, The Bob Parker Memorial Trust and the Peter MacCallum Cancer Centre Foundation. M.K. is supported by a NHMRC Senior Research Fellowship. P.D. is supported by a NHMRC Career Development Award, and M.S. is supported by an Australia Fellowship from the NHMRC.
- Nagata S: Apoptosis by death factor. Cell. 1997, 88: 355-365. 10.1016/S0092-8674(00)81874-7.PubMedView ArticleGoogle Scholar
- Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ: Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med. 2004, 199: 437-448. 10.1084/jem.20031457.PubMedPubMed CentralView ArticleGoogle Scholar
- French RR, Chan HT, Tutt AL, Glennie MJ: CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999, 5: 548-553. 10.1038/5505.PubMedView ArticleGoogle Scholar
- Kwon BS, Weissman SM: cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA. 1989, 86: 1963-1967. 10.1073/pnas.86.6.1963.PubMedPubMed CentralView ArticleGoogle Scholar
- Takahashi C, Mittler RS, Vella AT: Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol. 1999, 162: 5037-5040.PubMedGoogle Scholar
- Wen T, Bukczynski J, Watts TH: 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol. 2002, 168: 4897-4906.PubMedView ArticleGoogle Scholar
- Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazon A, Azpilikueta A, Ochoa MC, Alfaro C: Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008, 14: 6895-6906. 10.1158/1078-0432.CCR-08-0285.PubMedPubMed CentralView ArticleGoogle Scholar
- Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG: Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. J Clin Oncol. 2009Google Scholar
- Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J: Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008, 61: 82-90. 10.1016/j.lungcan.2007.12.011.PubMedView ArticleGoogle Scholar
- Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM: A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res. 2008, 14: 3450-3455. 10.1158/1078-0432.CCR-07-1416.PubMedView ArticleGoogle Scholar
- Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S: Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res. 2009, 15: 5584-5590. 10.1158/1078-0432.CCR-09-0996.PubMedView ArticleGoogle Scholar
- Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M: Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. J Clin Oncol. 2009Google Scholar
- Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yagita H, Smyth MJ: Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med. 2006, 12: 693-698. 10.1038/nm1405.PubMedView ArticleGoogle Scholar
- Teng MW, Westwood JA, Darcy PK, Sharkey J, Tsuji M, Franck RW, Porcelli SA, Besra GS, Takeda K, Yagita H: Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res. 2007, 67: 7495-7504. 10.1158/0008-5472.CAN-07-0941.PubMedView ArticleGoogle Scholar
- Smyth MJ, Teng MW, Sharkey J, Westwood JA, Haynes NM, Yagita H, Takeda K, Sivakumar PV, Kershaw MH: Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res. 2008, 68: 3019-3025. 10.1158/0008-5472.CAN-07-6019.PubMedView ArticleGoogle Scholar
- Murphy GP, Hrushesky WJ: A murine renal cell carcinoma. J Natl Cancer Inst. 1973, 50: 1013-1025.PubMedGoogle Scholar
- Teng MW, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ: CD1d-based combination therapy eradicates established tumors in mice. J Immunol. 2009, 183: 1911-1920. 10.4049/jimmunol.0900796.PubMedPubMed CentralView ArticleGoogle Scholar
- Most van der RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ: Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One. 2009, 4: e6982-10.1371/journal.pone.0006982.PubMedPubMed CentralView ArticleGoogle Scholar
- Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, Smyth MJ, Darcy PK, Kershaw MH: Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice. Clin Cancer Res. 2009, 15: 7624-7633. 10.1158/1078-0432.CCR-09-2201.PubMedView ArticleGoogle Scholar
- Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH: Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci USA. 2009, 106: 19455-19460. 10.1073/pnas.0909474106.PubMedPubMed CentralView ArticleGoogle Scholar
- Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH: IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest. 2001, 108: 51-62.PubMedPubMed CentralView ArticleGoogle Scholar
- Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986, 233: 1318-1321. 10.1126/science.3489291.PubMedView ArticleGoogle Scholar
- Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC: IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA. 2004, 101: 1969-1974. 10.1073/pnas.0307298101.PubMedPubMed CentralView ArticleGoogle Scholar
- Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL: Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol. 1991, 21: 851-854. 10.1002/eji.1830210350.PubMedView ArticleGoogle Scholar
- Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC: Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005, 11: 1238-1243. 10.1038/nm1312.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.